Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.57 |
| ▸ | GCGR | P47871 | 13/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14395788 | 0.91 | LMNA (0.57) | EGLN1GCGRMAOB | |
| SCHEMBL14124612 | 0.85 | SMN1; SMN2 (0.53) | EGLN1GCGRRAB9AMAOB | |
| SCHEMBL27482073 | 0.83 | GCGR (0.50) | GCGRMAOB | |
| SCHEMBL23417254 | 0.83 | EGLN1 (0.51) | EGLN1RAB9AMAOB | |
| SCHEMBL18667425 | 0.83 | MEN1 (0.52) | EGLN1RAB9AMAOB | |
| SCHEMBL14055876 | 0.81 | KDM4E (0.54) | GCGRMAOB | |
| SCHEMBL10228354 | 0.80 | CNR1 (0.57) | EGLN1RAB9AMAOB | |
| SCHEMBL31500499 | 0.80 | L3MBTL1 (0.59) | EGLN1MAOB | |
| SCHEMBL17820435 | 0.79 | EGLN1 (0.44) | EGLN1GCGRRAB9A | |
| SCHEMBL107387 | 0.76 | P2RX7 (0.53) | EGLN1RAB9AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, PTAFR, MPL | EGLN1 2095/4885GCGR 260/4885RAB9A 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.